Powered by: Motilal Oswal
2024-07-26 11:19:06 am | Source: Accord Fintech
Jubilant Ingrevia soars on raising Rs 100 crore through Commercial Papers

Jubilant Ingrevia is currently trading at Rs. 604.00, up by 12.65 points or 2.14% from its previous closing of Rs. 591.35 on the BSE.

The scrip opened at Rs. 582.65 and has touched a high and low of Rs. 606.45 and Rs. 582.65 respectively. So far 27530 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 616.90 on 15-Jul-2024 and a 52 week low of Rs. 407.00 on 1-Nov-2023.

Last one week high and low of the scrip stood at Rs. 606.45 and Rs. 524.30 respectively. The current market cap of the company is Rs. 9601.47 crore.

The promoters holding in the company stood at 51.47%, while Institutions and Non-Institutions held 20.62% and 27.90% respectively.

Jubilant Ingrevia has raised Rs 100 crore through Commercial Papers (CPs) on July 25, 2024. The maturity of the said Commercial Papers will be on September 20, 2024. Tenure of the instrument is 57 days. The Finance Committee, at its meeting held on August 18, 2023 approved issuance of Commercial Papers up to an amount of Rs 600 crore outstanding at any point of time, in one or more tranches.

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here